Perspective Therapeutics melanoma trial data set for SITC 2026 presentation
CATX•Perspective Therapeutics said its phase I/IIa [²¹²Pb]VMT01 melanoma data were accepted for presentation at SITC 2026 in Phoenix, with additional disclosure scheduled for Nov. 6, 2026. An interim readout showed early signs of tumor control in heavily pretreated patients, with safety broadly manageable.
1. Presentation and trial details
Perspective Therapeutics said its phase I/IIa [²¹²Pb]VMT01 melanoma data were accepted for presentation at SITC 2026 in Phoenix. Results were previously presented at ASCO 2026, and additional disclosure is scheduled for Nov. 6, 2026. The trial evaluates [²¹²Pb]VMT01 alone, with a separate arm testing it in combination with Bristol Myers Squibb’s nivolumab.
2. Interim findings
The interim readout showed early signs of tumor control in heavily pretreated patients, with safety broadly manageable.
